Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Thermo Fisher plans $2.1bn note sale to help fund Phadia buy

This article was originally published in Clinica

Executive Summary

Thermo Fisher Scientific is hoping to raise $2.1bn through a senior note sale to help pay for its €2.47 ($3.5bn) acquisition of Phadia. Thermo is planning to publicly offer $1bn of its 2.25% senior notes, due 2016, at an issue price of 99.826% of the principal amount; and $1.1bn of its 3.6% senior notes, due 2021, at an issue price of 99.809% of the principal amount. The note sale is expected to close on 16 August. Thermo agreed to purchase the Swedish allergy testing firm Phadia in May, in a move that will boost its speciality diagnostics offering (www.clinica.co.uk, 19 May 2011). The joint book-runners for the offering are Barclays Capital, Merrill Lynch, Pierce, Fenner & Smith, JP Morgan Securities, Deutsche Bank Securities, RBS Securities and Goldman, Sachs & Co.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT097730

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel